Nirman Agri Genetics Limited (NSEI: NIRMAN)
Health Care · Biotechnology · IN
Rs30.60
-10.00% today · -78.8% 1Y
Nirman Agri Genetics Limited (NSEI: NIRMAN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.56M and employs 38 people.
Over the last twelve months the share price has lost 78.8%, trading between 30.00 and 231.00.
Tweenvest scores Nirman Agri Genetics Limited across four factors: quality 63/100, value 76/100, growth 100/100, dividend 47/100. Its strongest factor is growth.
NIRMAN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.56M
- Revenue (TTM)
- $20.96M
- P/E
- 1.39
- EPS
- 21.98
- Dividend yield
- 6.54%
- Beta (5Y)
- 0.89
- 52-week high
- Rs231.00
- 52-week low
- Rs30.00
- Avg volume (3M)
- —
- Shares outstanding
- 8.01M
- Employees
- 38
- Next earnings
- —
About Nirman Agri Genetics Limited
Nirman Agri Genetics Ltd. is an Indian agri-input company primarily focused on the production, processing, and marketing of high-quality hybrid seeds. The company's product portfolio includes hybrid seeds for various field crops such as maize, paddy, bajra, sunflower, corn, and cotton, as well as vegetables like tomato, chili, okra, bitter gourd, cabbage, and capsicum. They also produce non-hybrid seeds, mainly for paddy. Beyond seeds, Nirman Agri Genetics offers a range of agricultural inputs including pesticides, bio-organics, bio-fertilizers, micronutrients, and plant growth regulators. The company operates a vertically integrated business model that encompasses research and development for breeding high-yielding, pest-resistant, and climate-resilient seed varieties, seed production through contract farmers, and distribution. Its target market is the farming community across India, with a current significant presence in states like Maharashtra, Gujarat, and Madhya Pradesh.
- Founded
- 2018
- Listed since
- Mar 28, 2023
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.